Citations (68)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Nazanin Aghel, Dakota Gustafson, Diego Delgado, Eshetu G. Atenafu, Jason E. Fish & Jeffrey H. Lipton. (2023) High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. Leukemia & Lymphoma 0:0, pages 1-10.
Read now
Read now
Grazia Casavecchia, Giuseppina Spinosa, Luisa De Gennaro, Stefano Zicchino, Matteo Gravina, Michele Magnesa, Matteo Di Biase & Natale Daniele Brunetti. (2022) Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors. Acta Cardiologica 77:2, pages 130-135.
Read now
Read now
Qian Wang, Changchuan Jiang, Yaning Zhang, Yu Zhang, Bing Yue, Binbin Zheng-Lin, Yang Zhao & Michael J. Mauro. (2020) Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results (SEER) analysis. Leukemia & Lymphoma 61:5, pages 1147-1157.
Read now
Read now
İlhami Gulçin & Parham Taslimi. (2018) Sulfonamide inhibitors: a patent review 2013-present. Expert Opinion on Therapeutic Patents 28:7, pages 541-549.
Read now
Read now
Prajwal Boddu, Abdul Rashid Shah, Gautam Borthakur, Srdan Verstovsek, Guillermo Garcia-Manero, Naval Daver, Tapan Kadia, Farhad Ravandi, Nitin Jain, Ahmad Alhuraiji, Jan Burger, Steven Kornblau, Sherry Pierce, Sara Dellasala, Elias Jabbour, Hagop Kantarjian & Jorge Cortes. (2018) Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leukemia & Lymphoma 59:6, pages 1312-1322.
Read now
Read now
Nazanin Aghel, Diego Hernan Delgado & Jeffrey Howard Lipton. (2017) Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vascular Health and Risk Management 13, pages 293-303.
Read now
Read now
Articles from other publishers (62)
Ricardo Roa-Chamorro, José Manuel Puerta-Puerta, Lucía Torres-Quintero, Fernando Jaén-Águila, Pablo González-Bustos, Miguel Ángel Rodríguez-Gil & Juan Diego Mediavilla-García. (2023) Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation. Scientific Reports 13:1.
Crossref
Crossref
A. N. Petrova, E. Yu. Chelysheva, I. S. Nemchenko, A. V. Bykova, M. A. Gurianova, E. A. Kuzmina, N. N. Tsyba, A. V. Kokhno & A. G. Turkina. (2023) A long-term follow-up of observation in treatment-free remission in patients with chronic myeloid leukemia. Russian journal of hematology and transfusiology 68:1, pages 21-34.
Crossref
Crossref
Takuo Nomura & Akito Hata. (2023) Limb Salvage Surgery for Ponatinib-Induced Bilateral Chronic Limb-Threatening Ischemia in a Patient with Chronic Myeloid Leukemia with T315I Mutation in BCR-ABL: A Case Report. Annals of Vascular Diseases.
Crossref
Crossref
Yuko Kanbayashi, Mayako Uchida, Kana Nakano, Haruka Wakabayashi & Tadashi Shimizu. (2023) Evaluation of Cardiac Adverse Events with Ponatinib Using a Spontaneous Reporting Database. Oncology 101:6, pages 397-405.
Crossref
Crossref
Yu Chien Yang, Ru Yu Huang, Hui Jen Tsai, Po Chih Li, Yi Hsin Yang & Kun Pin Hsieh. (2022) Cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors in Taiwan: a nationwide population-based study. European Journal of Preventive Cardiology 29:9, pages 1312-1321.
Crossref
Crossref
Akihiro Hirayama, Takatoshi Sorimachi, Kazuma Yokota, Hideaki Shigematsu, Kittipong Srivatanakul & Mitsunori Matsumae. (2021) New-generation tyrosine kinase inhibitor-associated asymptomatic cerebrovascular stenosis: two illustrative cases. Acta Neurochirurgica 164:6, pages 1623-1626.
Crossref
Crossref
Jae Eun Sim, Jeongho Park & Oh Young Bang. (2021) Non-thrombotic ischemic cerebrovascular events related to the use of tyrosine kinase inhibitors in patients with cancer: high-resolution magnetic resonance imaging findings. Precision and Future Medicine 5:4, pages 199-203.
Crossref
Crossref
Qiongnan Di, Huiyang Deng, Yingxin Zhao, Bo-ya Li & Ling Qin. (2021) Second-Generation Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response: A Systematic Review and a Meta-Analysis. Computational and Mathematical Methods in Medicine 2021, pages 1-9.
Crossref
Crossref
Bala Pushparaji, Teodora Donisan, Dinu V. Balanescu, Nicolas Palaskas, Peter Kim, Juan Lopez-Mattei, Mehmet Cilingiroglu, Saamir A. Hassan, Konstantinos Dean Boudoulas, Konstantinos Marmagkiolis, Ludhmila Abrahao Hajjar & Cezar A. Iliescu. (2021) Interventional Strategies in Cancer-induced Cardiovascular Disease. Current Oncology Reports 23:11.
Crossref
Crossref
Mei-Tsen Chen, Shih-Tsung Huang, Chih-Wan Lin, Bor-Sheng Ko, Wen-Jone Chen, Huai-Hsuan Huang & Fei-Yuan Hsiao. (2021)
Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A
Population-Based
, Propensity
Score-Matched
Cohort Study
. The Oncologist 26:11, pages 974-982.
Crossref
Crossref
Olga Mulas, Giovanni Caocci, Brunella Mola & Giorgio La Nasa. (2021) Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Ricardo Roa-Chamorro, Fernando Jaén-Águila, José Manuel Puerta-Puerta, Lucía Torres-Quintero, Pablo González-Bustos & Juan Diego Mediavilla-García. (2021) Arterial hypertension assessment in a population with chronic myeloid leukemia. Scientific Reports 11:1.
Crossref
Crossref
B. Muresan, C. Mamolo, J. C. Cappelleri, M. J. Postma & B. Heeg. (2021) Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting. Applied Health Economics and Health Policy.
Crossref
Crossref
Darryl Leong, Nazanin Aghel, Christopher Hillis, Deborah Siegal, Sarah Karampatos, Sumathy Rangarajan, Gregory Pond & Hsien Seow. (2021) Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease. Heart 107:8, pages 667-673.
Crossref
Crossref
Dragana Milojkovic, Nicholas C. P. Cross, Sahra Ali, Jenny Byrne, Gavin Campbell, Fiona L. Dignan, Mark Drummond, Brian Huntly, Scott Marshall, Mary Frances McMullin, Pratap Neelakantan, Manoj Raghavan, Muttuswamy Sivakumaran, Jane Tighe, Farooq Wandroo, Fenella Willis, Fiona Glen, Louise Fildes, Sarah J. Collington, Jacqueline Ryan, Richard E. Clark & Adam J. Mead. (2020) Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. British Journal of Haematology 192:1, pages 62-74.
Crossref
Crossref
Joerg Herrmann. 2021. Atlas of Imaging in Cardio-Oncology. Atlas of Imaging in Cardio-Oncology
51
54
.
Graeme Smith, Jane Apperley, Dragana Milojkovic, Nicholas C. P. Cross, Letizia Foroni, Jenny Byrne, Andy Goringe, Anupama Rao, Jamshid Khorashad, Hugues Lavallade, Adam J. Mead, Wendy Osborne, Chris Plummer, Gail Jones & Mhairi Copland. (2020) A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. British Journal of Haematology 191:2, pages 171-193.
Crossref
Crossref
E Spina, R Renna, LA Lanterna, ML Colleoni & V Andreone. (2020) Progressive thrombosis of cervical and intracranial arteries related to Ponatinib treatment for Chronic Myeloid Leukemia. Journal of Stroke and Cerebrovascular Diseases 29:9, pages 105085.
Crossref
Crossref
Joerg Herrmann. (2020) Vascular toxic effects of cancer therapies. Nature Reviews Cardiology 17:8, pages 503-522.
Crossref
Crossref
Jessica Potts, Mohamed O. Mohamed, Juan C. Lopez Mattei, Cezar A. Iliescu, Marina Konopleva, Muhammad Rashid, Rodrigo Bagur & Mamas A. Mamas. (2019) Percutaneous coronary intervention and in‐hospital outcomes in patients with leukemia: a nationwide analysis. Catheterization and Cardiovascular Interventions 96:1, pages 53-63.
Crossref
Crossref
Deepak Bansal. (2020) Chronic Myeloid Leukemia in Children: Challenges and Opportunities. The Indian Journal of Pediatrics 87:6, pages 443-450.
Crossref
Crossref
Hélène Haguet, Carlos Graux, François Mullier, Jean-Michel Dogné & Jonathan Douxfils. (2020) Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis. Cancers 12:5, pages 1242.
Crossref
Crossref
Ashley L. Cole, William A. WoodJrJr, Benyam Muluneh, Jennifer L. Lund, Jennifer Elston Lafata & Stacie B. Dusetzina. (2020) Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib. JCO Oncology Practice 16:5, pages e443-e455.
Crossref
Crossref
Ricardo Roa-Chamorro, Lucía Torres-Quintero, Carlos García de los Ríos, José Manuel Puerta-Puerta, Pablo González-Bustos & Juan Diego Mediavilla-García. (2020) Enfermedad cardiovascular progresiva en paciente bajo tratamiento con nilotinib. Clínica e Investigación en Arteriosclerosis 32:2, pages 66-69.
Crossref
Crossref
Ricardo Roa-Chamorro, Lucía Torres-Quintero, Carlos García de los Ríos, José Manuel Puerta-Puerta, Pablo González-Bustos & Juan Diego Mediavilla-García. (2020) Progressive cardiovascular disease in a patient under treatment with nilotinib. Clínica e Investigación en Arteriosclerosis (English Edition) 32:2, pages 66-69.
Crossref
Crossref
L.M. Makeeva, E.I. Emelina, A.V. Bykova, Gennadii Efimovich Gendlin, G.A. Gusarova, I.G. Nikitin, E.Yu. Chelysheva, O.Yu. Vinogradova, I.E. Lazarev, E.G. Arshanskaya & A.G. Turkina. (2020) Comparative Analysis of Cardiovascular Disorders in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitor Therapy. Clinical oncohematology 13:1, pages 104-111.
Crossref
Crossref
Dinu Valentin Balanescu, Teodora Donisan, Konstantinos Marmagkiolis & Cezar Iliescu. 2020. Oncologic Critical Care. Oncologic Critical Care
787
806
.
Hiroyuki Kiriyama, Junichi Ishida, Hiroshi Kadowaki, Takeshi Iwasa, Arihiro Kiyosue, Satoshi Kodera, Jiro Ando, Hiroshi Akazawa & Issei Komuro. (2019) OCT-Based Management of Nilotinib-Associated CAD in a Patient With Chronic Myeloid Leukemia. JACC: CardioOncology 1:2, pages 318-321.
Crossref
Crossref
Naranie Shanmuganathan & Timothy P. Hughes. (2019) Early Management of CML. Current Hematologic Malignancy Reports 14:6, pages 480-491.
Crossref
Crossref
A. N. Petrova, E. Yu. Chelysheva & A. G. Turkina. (2019) Treatment-free remission in patients with chronic myeloid leukemia: literature review. Oncohematology 14:3, pages 12-22.
Crossref
Crossref
Abdul Rahim, Riyaz Syed, Y. Poornachandra, M. Shaheer Malik, Ch. Venkata Ramana Reddy, Mallika Alvala, Kiran Boppana, B. Sridhar, Ramars Amanchy & Ahmed Kamal. (2019) Synthesis and biological evaluation of phenyl-amino-pyrimidine and indole/oxindole conjugates as potential BCR-ABL inhibitors. Medicinal Chemistry Research 28:5, pages 633-645.
Crossref
Crossref
Adrian G. Minson, Katherine CumminsLucy FoxBen CostelloDavid YeungRebecca ClearyCecily ForsythMaciek TatarczuchKate BurburyOlga MotornaJake ShorttShaun FlemingAndrew McQuillanAnthony SchwarerRosemary HarrupAmy HolmesSumita RatnasingamKah-Lok ChanWei-Hsun Hsu, Asma Ashraf, Faye PuttAndrew Grigg. (2019) The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia. Blood Advances 3:7, pages 1084-1091.
Crossref
Crossref
Masahiro Kizaki, Naoto Takahashi, Noriyoshi Iriyama, Shinichiro Okamoto, Takaaki Ono, Noriko Usui, Koiti Inokuchi, Chiaki Nakaseko, Mineo Kurokawa, Masahiko Sumi, Fumihiko Nakamura, Tatsuya Kawaguchi, Ritsuro Suzuki, Kazuhito Yamamoto, Kazunori Ohnishi, Itaru Matsumura & Tomoki Naoe. (2019) Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. International Journal of Hematology 109:4, pages 426-439.
Crossref
Crossref
Akihiko Nakaya, Masahiro Ebitani, Tatsuya Monzen, Takuro Nagno, Futoshi Saito & Yukihiro Yaoita. (2019) A case of recurrent cerebral infarction during treatment with oral tyrosine kinase inhibitors for chronic myelogenous leukemiaチロシンキナーゼ阻害薬（tyrosin kinase inhibitor; TKI）を内服中に脳梗塞を繰り返した1例. Rinsho Shinkeigaku 59:7, pages 418-424.
Crossref
Crossref
Giuseppina Novo, Daniela Di Lisi, Manuela Fiuza & Fausto J. Pinto. 2019. Cardiovascular Complications in Cancer Therapy. Cardiovascular Complications in Cancer Therapy
45
55
.
Dinu Valentin Balanescu, Teodora Donisan, Konstantinos Marmagkiolis & Cezar Iliescu. 2019. Oncologic Critical Care. Oncologic Critical Care
1
20
.
Tariq I. Mughal, Thomas Lion, Omar Abdel‐Wahab, Ruben Mesa, Robyn M. Scherber, Danilo Perrotti, Michael Mauro, Srdan Verstovsek, Giuseppe Saglio, Richard A. Van Etten & Robert Kralovics. (2018) Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. Hematological Oncology 36:5, pages 740-748.
Crossref
Crossref
Kohei Suzuki, Junkoh Yamamoto, Shingo Kakeda, Seishiro Takamatsu, Ryo Miyaoka, Takehiro Kitagawa, Takeshi Saito, Yoshiteru Nakano & Shigeru Nishizawa. (2018) Vessel wall magnetic resonance imaging findings and surgical treatment in nilotinib‑associated cerebrovascular disease: A case report. Molecular and Clinical Oncology.
Crossref
Crossref
Ching-Jen Chen, Brian J Sorace, Aria Shakeri, Min S Park, Andrew M Southerland, Bradford B Worrall & M Yashar S Kalani. (2018) Republished: Tyrosine kinase inhibitor induced rapidly progressive vasculopathy after intracranial stent placement. Journal of NeuroInterventional Surgery 10:11, pages e28-e28.
Crossref
Crossref
Maël Heiblig, Delphine Rea, Marie-Lorraine Chrétien, Aude Charbonnier, Philippe Rousselot, Valérie Coiteux, Martine Escoffre-Barbe, Viviane Dubruille, Françoise Huguet, Emilie Cayssials, Eric Hermet, Agnès Guerci-Bresler, Shanti Amé, Lucila Sackmann-Sala, Lydia Roy, Mohamad Sobh, Stéphane Morisset, Gabriel Etienne & Franck E. Nicolini. (2018) Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study. Experimental Hematology 67, pages 41-48.
Crossref
Crossref
Tariq I. Mughal, Giuseppe Saglio & Richard A. Van Etten. (2018) Chronic Myeloproliferative Neoplasms: Some Remaining Challenges. HemaSphere 2:5, pages e147.
Crossref
Crossref
Shinsuke Noguchi, Chiaki Nakaseko, Kaichi Nishiwaki, Hitoshi Ogasawara, Kohshi Ohishi, Michihide Tokuhira, Masaaki Noguchi, Hideo Kimura, Hiroshi Handa, Kinuko Mitani, Masatomo Miura, Hisashi Wakita & Naoto Takahashi. (2018) Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan. International Journal of Hematology 108:2, pages 176-183.
Crossref
Crossref
Sanil Bhatia, Daniela DiedrichBenedikt Frieg, Heinz Ahlert, Stefan SteinBertan BoppFranziska Lang, Tao ZangTobias KrögerThomas ErnstGesine Kögler, Andreas KriegSteffen LüdekeHana KunkelAna J. Rodrigues MoitaMatthias U. KassackViktoria MarquardtFriederike V. Opitz, Marina Oldenburg, Marc RemkeFlorian Babor, Manuel GrezAndreas HochhausArndt Borkhardt, Georg Groth, Luitgard Nagel-StegerJoachim JoseThomas Kurz, Holger Gohlke, Finn K. Hansen & Julia Hauer. (2018) Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. Blood 132:3, pages 307-320.
Crossref
Crossref
Julie C. Birch, Gaurav KhatriLori M. WatumullYull E. ArriagaJohn R. Leyendecker. (2018) Unintended Consequences of Systemic and Ablative Oncologic Therapy in the Abdomen and Pelvis. RadioGraphics 38:4, pages 1158-1179.
Crossref
Crossref
Emanuel Raschi, Igor Diemberger, Benilde Cosmi & Fabrizio De Ponti. (2018) ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations—authors’ reply. Internal and Emergency Medicine 13:4, pages 635-636.
Crossref
Crossref
Ching-Jen Chen, Brian J Sorace, Aria Shakeri, Min S Park, Andrew M Southerland, Bradford B Worrall & M Yashar S Kalani. (2018) Tyrosine kinase inhibitor induced rapidly progressive vasculopathy after intracranial stent placement. BMJ Case Reports, pages bcr-2018-013777.
Crossref
Crossref
David M. Ross, Chris Arthur, Kate Burbury, Brian S. Ko, Anthony K. Mills, Jake Shortt & Karam Kostner. (2018) Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors. Internal Medicine Journal 48, pages 5-13.
Crossref
Crossref
Chikara HIRASE & Itaru MATSUMURA. (2018) Thromboembolism in TKI therapyチロシンキナーゼ阻害薬（TKI）治療と血栓塞栓症. Japanese Journal of Thrombosis and Hemostasis 29:5, pages 473-486.
Crossref
Crossref
I. Brana, E. Zamora, G. Oristrell & J. Tabernero. 2018. Side Effects of Medical Cancer Therapy. Side Effects of Medical Cancer Therapy
367
406
.
Nazanin Aghel, Jeffrey Howard Lipton, Eshetu G. Atenafu, Dennis Dong Hwan Kim & Diego Hernan Delgado. (2017) Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up. Clinical Lymphoma Myeloma and Leukemia 17:12, pages 870-878.e1.
Crossref
Crossref
Tomohiko Ozaki, Hajime Nakamura, Nobuyuki Izutsu, Hiroaki Masaie, Jun Ishikawa & Manabu Kinoshita. (2017) Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia. Interventional Neuroradiology 23:5, pages 527-530.
Crossref
Crossref
Naoto Takahashi, Chiaki Nakaseko, Yukio Kobayashi, Koichi Miyamura, Chiho Ono, Yuichiro Koide, Yosuke Fujii & Kazunori Ohnishi. (2017) Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment. International Journal of Hematology 106:3, pages 398-410.
Crossref
Crossref
Peter Valent, Emir Hadzijusufovic, Gregor Hoermann, Wolfgang Füreder, Gerit-Holger Schernthaner, Wolfgang R. Sperr, Rudolf Kirchmair & Dominik Wolf. (2017) Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leukemia Research 59, pages 47-54.
Crossref
Crossref
Koung Jin Suh, Ji Yun Lee, Dong-Yeop Shin, Youngil Koh, Soo-Mee Bang, Sung-Soo Yoon, Seonyang Park, Inho Kim & Jeong-Ok Lee. (2017) Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials. International Journal of Hematology 106:2, pages 229-239.
Crossref
Crossref
Giuseppe Saglio, Philipp le Coutre, Jorge Cortes, Jiří Mayer, Philip Rowlings, François-Xavier Mahon, Glenn Kroog, Kyna Gooden, Milayna Subar & Neil P. Shah. (2017) Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. Annals of Hematology 96:8, pages 1303-1313.
Crossref
Crossref
A. G. Turkina, E. Yu. Chelysheva, V. A. Shuvaev, G. A. Gusarova, A. V. Bykova, O. A. Shukhov, A. N. Petrova, M. V. Vakhrusheva, S. R. Goryacheva, L. Yu. Kolosova, P. S. Krasikova, M. S. Fominykh, I. S. Martynkevich, A. O. Abdullaev, A. B. Sudarikov & V. G. Savchenko. (2017) Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy. Terapevticheskii arkhiv 89:12, pages 86.
Crossref
Crossref
Takahiro Yoshida, Ei Leen Liew, Mihoko Ota, Hiroshi Nakayama, Yasuo Yanagihara, Yuki Nakamura, Taku Seriu & Masaru Kamishohara. (2017) Pharmacological characteristics and clinical outcomes of ponatinib (Iclusig<sup>®</sup>), a third-generation tyrosine kinase inhibitor. Folia Pharmacologica Japonica 150:1, pages 54-61.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
641
693
.
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
481
504
.
S. Dent, A. Law, O. Aseyev, N. Ghosh & C. Johnson. 2017. Cardio-Oncology. Cardio-Oncology
221
236
.
Srila GopalKenneth B. MillerIris Z. Jaffe. (2016) Molecular mechanisms for vascular complications of targeted cancer therapies. Clinical Science 130:20, pages 1763-1779.
Crossref
Crossref
P D le Coutre, T P Hughes, F-X Mahon, D-W Kim, J L Steegmann, N P Shah, K Gooden, N Wallis & J E Cortes. (2015) Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. Leukemia 30:7, pages 1593-1596.
Crossref
Crossref